Arsenic trioxide neurotoxicity in acute promyelocytic leukemia patients: a single center experience.

The document discusses the neurotoxicity associated with arsenic trioxide (ATO) treatment in patients with acute promyelocytic leukemia (APL). ATO, used in combination with all-trans retinoic acid (ATRA), is the standard treatment for non-high-risk APL, but it can lead to various neurological adverse effects. The text presents three cases of severe neurological toxicity during ATO treatment, highlighting the importance of early recognition and management of neurotoxicity in APL patients. The document also emphasizes the need for further research to better understand and prevent ATO neurotoxicity. [Extracted from the article]